A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding

PHASE3TerminatedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

March 30, 2018

Primary Completion Date

July 12, 2021

Study Completion Date

July 12, 2021

Conditions
Uterine Fibroids and Heavy Menstrual Bleeding
Interventions
DRUG

Vilaprisan (BAY1002670)

2mg, once daily, oral

Trial Locations (25)

451-8511

Meitetsu Hospital, Nagoya

460-0011

Kano's Clinic for Women, Nagoya

274-0063

Kyoritsu Narashinodai Hospital, Funabashi

820-8505

Aso Iizuka Hospital, Iizuka

963-8585

Jusendo Geneal Hospital Yuasa Foundation, Kōriyama

370-0836

Sato Hospital, Takasaki

004-0052

Hashimoto Clinic, Sapporo

064-0808

Yoshio Clinic, Sapporo

760-0076

Asahi-Clinic., Takamatsu

710-0824

Kurashiki Medical Clinic, Kurashiki

340-0028

Medical Topia Soka Hospital, Sōka

112-0014

Sei Womens Clinic, Bunkyo

104-8560

St.Luke's International Hospital, Chuoku

183-0056

Akazawa Clinic, Fuchū

105-0001

Toranomon Womens Clinic, Minato

107-0051

Akasakamitsuke Miyazaki Obstetrics and Gynecology Clinic, Minato

108-0014

Yokokura Clinic, Minato-ku

162-8666

Tokyo Women's Medical University Hospital, Shinjuku-ku

910-0845

Kato Internal medicine and Gynecology Clinic, Fukui

810-8539

Hamanomachi Hospital, Fukuoka

530-0013

Medical corporation keizukai Chayamachi Ladies Clinic, Osaka

542-0076

Medical Corporation Koshinkai Nomura Clinic Namba, Osaka

543-0023

Izuma Clinic, Osaka

422-8527

Shizuoka Saiseikai General Hospital, Shizuoka

930-8550

Toyama Prefectural Central Hospital, Toyama

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY